The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Roche provides community update on FIREFISH & SUNFISH studies of risdiplam

    Roche has provided us with the following statement on the FIREFISH and SUNFISH studies of risdiplam: Dear SMA community, We are happy to share an update on our FIREFISH and SUNFISH studies of risdiplam. We would also like to acknowledge the tremendous support and partnership of SMA Patient Groups around the world and to thank […]


  2. RG7916 community update from Roche

    Roche has shared with us an update of the RG7916, now called risdiplam, programme, which has reached a number of milestones. Risdiplam is an SMN2 splicing modifier which is given daily by mouth or by g-tube as a liquid and distributes widely throughout the body. Risdiplam has been designed to help the SMN2 gene produce more […]


  3. Roche ends development of olesoxime

    It was announced today that Roche has taken the difficult decision of ending the development of neuro-protective compound Olesoxime. In 2016 Roche started the OLEOS study, an open label extension study evaluating the long term safety and effectiveness of olesoxime. Many discussions with Health Authorities (FDA and EMA) and SMA experts were had and the […]